Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study.
Frahm N, Fneish F, Ellenberger D, Haas J, Löbermann M, Peters M, Pöhlau D, Röper AL, Schilling S, Stahmann A, Temmes H, Paul F, Zettl UK. Frahm N, et al. Among authors: peters m. J Clin Med. 2023 May 24;12(11):3640. doi: 10.3390/jcm12113640. J Clin Med. 2023. PMID: 37297838 Free PMC article.
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study.
Frahm N, Fneish F, Ellenberger D, Haas J, Loebermann M, Parciak T, Peters M, Pöhlau D, Rodgers J, Röper AL, Schilling S, Stahmann A, Temmes H, Zettl UK, Middleton RM. Frahm N, et al. Among authors: peters m. Lancet Reg Health Eur. 2022 Sep 2;22:100502. doi: 10.1016/j.lanepe.2022.100502. eCollection 2022 Nov. Lancet Reg Health Eur. 2022. PMID: 36090519 Free PMC article.
Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study.
Fneish F, Frahm N, Peters M, Ellenberger D, Haas J, Löbermann M, Pöhlau D, Röper AL, Schilling S, Stahmann A, Temmes H, Paul F, Zettl UK. Fneish F, et al. Among authors: peters m. Vaccines (Basel). 2023 Dec 16;11(12):1859. doi: 10.3390/vaccines11121859. Vaccines (Basel). 2023. PMID: 38140262 Free PMC article.
Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
Frahm N, Ellenberger D, Stahmann A, Fneish F, Lüftenegger D, Salmen HC, Schirduan K, Schaak TPA, Flachenecker P, Kleinschnitz C, Paul F, Krefting D, Zettl UK, Peters M, Warnke C. Frahm N, et al. Among authors: peters m. Ther Adv Neurol Disord. 2024 Mar 29;17:17562864241239740. doi: 10.1177/17562864241239740. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38560408 Free PMC article.
Evaluation of Phoenix Sepsis Score Criteria: Exploratory Analysis of Characteristics and Outcomes in an Emergency Transport PICU Cohort From the United Kingdom, 2014-2016.
Carter MJ, Hageman J, Feinstein Y, Herberg J, Kaforou M, Peters MJ, Nadel S, Edmonds N, Pathan N, Levin M, Ramnarayan P. Carter MJ, et al. Among authors: peters mj. Pediatr Crit Care Med. 2025 Jan 3. doi: 10.1097/PCC.0000000000003682. Online ahead of print. Pediatr Crit Care Med. 2025. PMID: 39750062
4,188 results